Synthetic lethal targeting of lobular breast cancer
The inactivation of tumour suppressor genes is the most common of all genetic events in cancer but not one that can be targeted by conventional therapy, because the tumour suppressor protein is lost from the cancer cell. However, the loss of these genes is predicted to create vulnerabilities in the cancer cell that can nevertheless be targeted with drugs. We have compelling data showing that the loss the tumour suppressor gene CDH1, an event that is a hallmark the lobular subtype of breast cancer, creates vulnerabilities which can be targeted with drugs. In this project, we will develop new breast cancer treatments which exploit these vulnerabilities.
Keep reading
View all
From Evidence to Action: Expanding the ‘Not a One-Size-Fits-All’ Breast Cancer Screening Model for Aotearoa New Zealand.
Problem:Breast cancer screening in Aotearoa New Zealand does not benefit all women equally. Many cancers are still found outside the national screening programme, and Māori and Pacific women can fa...
Using Deep Learning And Digital Pathology To Intrinsically Subtype Breast Cancer
Problem:Traditional pathology uses microscopes to examine tissue slides, but this method can be slow and inconsistent, and not all patients can afford advanced molecular testing. Project:Digital pa...
“Shielding” Macrophages: Uncovering Immune-Mediated Chemoresistance in Triple-Negative Breast Cancer
ProblemTriple-negative breast cancer (TNBC) is one of the hardest types to treat and affects Māori and Pacific women more than others. Many patients with TNBC don’t fully respond to chemotherapy, a...
